Leveraging the natural tolerance induction capabilities of the liver.

Topas’ technology platform induces antigen-specific immune tolerance by utilizing the liver’s natural immunology capabilities. We target liver sinusoidal endothelial cells (LSECs), which generate tolerance against bloodborne antigens. Topas’ peptide-loaded nanoparticles mimic such bloodborne antigens and follow their natural processing in LSECs, including the generation of long-lasting antigen-specific regulatory T-cells (Tregs). This allows us to develop novel therapeutic solutions for autoimmune diseases, allergies and anti-drug antibodies.

Latest News

2018-04-24 – Press release

Topas Therapeutics and Boehringer Ingelheim Sign Multi-Year Collaboration and Option Agreement

read more …

2018-01-25 – Press release

Topas Therapeutics serves as exclusive translational partner for Collaborative Research Center focused on liver inflammation at University Medical Center Hamburg-Eppendorf

read more …

2017-11-02 – Press release

Topas Therapeutics extends its Series A to EUR 18 Million (USD 21 Million) with Boehringer Ingelheim Venture Fund

read more …